Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MEXATE-AQ vs AGRYLIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Methotrexate is a folate analog that inhibits dihydrofolate reductase (DHFR), blocking the conversion of dihydrofolate to tetrahydrofolate, which is required for the synthesis of purines and pyrimidines. This leads to inhibition of DNA, RNA, and protein synthesis, particularly in rapidly dividing cells. It also has immunosuppressive effects via inhibition of T cell activation and reduction of inflammatory cytokines.
Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.
FDA-approved: Chemotherapy for gestational choriocarcinoma, chorioadenoma destruens, hydatidiform mole, acute lymphocytic leukemia, meningeal leukemia, breast cancer, head and neck cancer, cutaneous T-cell lymphoma, lung cancer, non-Hodgkin's lymphoma, osteosarcoma, and mycosis fungoides.,FDA-approved: Severe, active rheumatoid arthritis (RA) in adults who have failed first-line therapy.,FDA-approved: Pediatric patients with polyarticular juvenile idiopathic arthritis (p JIA) who have failed first-line therapy.,FDA-approved: Psoriasis (severe, recalcitrant) in adults.,Off-label: Prevention of graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation.,Off-label: Crohn's disease (maintenance of remission in steroid-dependent patients).,Off-label: Ectopic pregnancy (medical management).
Essential thrombocythemia (ET) to reduce elevated platelet counts and the risk of thrombotic complications
Methotrexate: 7.5-25 mg orally once weekly for rheumatoid arthritis; 30-40 mg/m2 IV weekly for mycosis fungoides; 50-75 mg/m2 IV over 4-6 hours weekly for osteosarcoma; 15-20 mg/m2 IM weekly for psoriasis.
Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.
Terminal elimination half-life is approximately 3–10 hours for low doses (<30 mg/m²) and 8–15 hours for high doses (>80 mg/m²). Prolonged to 48–72 hours in patients with third-space effusions or renal impairment.
Terminal elimination half-life: 1.3–1.5 days (31–36 hours) in patients with ET; allows twice-daily dosing.
Metabolized primarily in the liver to polyglutamates (which are active metabolites) via folylpolyglutamate synthetase. Partial metabolism via aldehyde oxidase and xanthine oxidase to 7-hydroxymethotrexate. Methotrexate is also partially metabolized by intestinal flora. Elimination is primarily renal via glomerular filtration and active tubular secretion.
Primarily metabolized by CYP1A2 to the active metabolite 3-hydroxyanagrelide, and to a lesser extent by CYP2C19 and CYP2D6.
Renal excretion predominates (80-90% as unchanged drug) via glomerular filtration and active tubular secretion. Biliary/fecal elimination is minor (<10%).
Renal: 80% (primarily unchanged drug), Biliary/Fecal: 5%
Approximately 50–60% bound primarily to albumin. Weakly bound and readily displaceable by other drugs.
82–88% bound to plasma proteins (primarily albumin).
Vd: 0.4–0.8 L/kg (initial 0.18 L/kg, steady-state 0.4–0.8 L/kg). Distributes into third-space fluids (pleural, ascitic), leading to prolonged elimination.
30–36 L (approximately 0.45–0.5 L/kg for a 70 kg adult); indicates extensive tissue distribution.
Oral: 30–60% (dose-dependent; saturable absorption at high doses). Intramuscular: 80–100%. Subcutaneous: approximately 90%.
Oral: 65–80% (median 73%)
For GFR 40-59 m L/min: reduce dose by 20%; GFR 20-39 m L/min: reduce dose by 40%; GFR <20 m L/min: contraindicated.
No specific GFR-based recommendations; use with caution in renal impairment (Cr Cl <50 m L/min) and monitor closely.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Child-Pugh A: No adjustment. Child-Pugh B or C: Reduce initial dose by 50% and titrate cautiously.
For acute lymphoblastic leukemia (ALL): 15-20 mg/m2 IM once weekly as maintenance; for osteosarcoma: 12 g/m2 IV over 4 hours with leucovorin rescue.
Children ≥7 years: 0.5 mg orally once or twice daily; adjust based on platelet response. Maximum: 10 mg/day. Not established for <7 years.
Start at lowest recommended dose (e.g., 5 mg orally once weekly) with careful monitoring for renal function, hepatic function, and folate levels; adjust based on tolerance.
No specific adjustment; start at lower end of dosing range (0.5 mg twice daily) and monitor renal function and platelet counts closely.
Boxed Warning: Methotrexate can cause fetal death or teratogenic effects when administered to pregnant women. It is contraindicated in pregnant women with psoriasis or RA. It also has a boxed warning for severe toxicity and death due to inadvertent daily (as opposed to weekly) dosing; hepatic toxicity, including acute hepatitis and chronic hepatic fibrosis; myelosuppression, including severe bone marrow suppression; and pulmonary toxicity, including acute or chronic interstitial pneumonitis. Additionally, anaphylactic reactions can occur. For patients with psoriasis, methotrexate should be used only for severe, recalcitrant cases unresponsive to other therapy.
None
Fatal toxicities (including hematologic, hepatic, pulmonary, renal, dermatologic, and GI) can occur with methotrexate; monitor closely.,Hepatic toxicity: Monitor liver function tests; avoid or use with caution in patients with active liver disease or alcohol abuse.,Pulmonary toxicity: Acute or chronic interstitial pneumonitis may occur; monitor for cough, fever, dyspnea, and hypoxia.,Myelosuppression: Monitor CBC and platelet counts regularly; severe pancytopenia can occur.,Renal toxicity: Adequate renal function is essential; avoid NSAIDs, salicylates, and other nephrotoxic drugs if possible.,Gastrointestinal toxicity: Mucositis, ulcerative stomatitis, diarrhea, and hemorrhagic enteritis may occur.,Dermatologic toxicity: Phototoxicity, radiation recall, and severe skin reactions (including Stevens-Johnson syndrome) can occur.,Immunosuppression: Increased risk of infections, including opportunistic infections; avoid live vaccines.,Carcinogenicity: Increased risk of lymphoproliferative disorders (may be reversible with discontinuation).,Concomitant use with proton pump inhibitors (PPIs) may increase methotrexate levels.
Cardiovascular risks: increased risk of ventricular tachycardia, QTc prolongation, and heart failure; use caution in patients with known cardiac disease.,Hematologic effects: monitor complete blood counts regularly due to risk of anemia, leukopenia, or thrombocytopenia.,Hepatic impairment: reduce dose in patients with moderate to severe hepatic impairment.,Renal impairment: use with caution in severe renal impairment.
Hypersensitivity to methotrexate or any component of the formulation.,Pregnancy and breastfeeding (due to risk of fetal death/teratogenicity and excretion in breast milk).,Patients with psoriasis or RA who have alcoholism, alcoholic liver disease, chronic liver disease, or overt immunodeficiency.,Pre-existing blood dyscrasias (severe anemia, leukopenia, neutropenia, thrombocytopenia).,Concomitant use with live vaccines.
Severe hepatic impairment,Known hypersensitivity to anagrelide or any component of the formulation
Avoid folic acid-rich foods (leafy greens, fortified grains) in large amounts during methotrexate therapy as they may reduce efficacy. No specific food-drug interactions; maintain a well-balanced diet.
Grapefruit and grapefruit juice should be avoided as they may increase anagrelide plasma concentrations. No other specific dietary restrictions; however, maintain adequate hydration to reduce risk of crystalluria.
FDA Pregnancy Category X. First trimester: High risk of miscarriage, CNS defects, craniofacial anomalies. Second trimester: IUGR, skeletal abnormalities. Third trimester: Neonatal bone marrow suppression, immunosuppression.
Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies) at doses less than the human therapeutic dose. There are no adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies potential risk to fetus. First trimester: Avoid due to organogenesis risk. Second and third trimesters: Unknown risks; consider alternative therapy.
Contraindicated. Methotrexate is excreted in breast milk; accumulation may occur in nursing infants due to immature renal function. M/P ratio not established; theoretical risk of serious adverse effects.
It is not known whether anagrelide is excreted in human milk. No M/P ratio is available. Due to potential for serious adverse reactions in breastfed infants (e.g., thrombocytopenia, cardiovascular effects), advise women not to breastfeed during treatment and for at least 7 days after last dose.
Contraindicated in pregnancy; no dose adjustment recommended due to teratogenicity. In lactating females, discontinue breastfeeding or avoid use.
No specific pharmacokinetic studies in pregnancy. Pregnancy-induced plasma volume expansion may lower drug concentrations, potentially requiring dose adjustment to maintain therapeutic effect. However, due to teratogenicity risks, avoid use in pregnancy. If necessary, start at lowest effective dose (0.5 mg/day) and titrate based on platelet count monitoring, not to exceed 10 mg/day.
Mexate-AQ (methotrexate) requires folic acid supplementation to reduce gastrointestinal and hematologic toxicity. Administer leucovorin rescue after high-dose therapy. Avoid NSAIDs, salicylates, and sulfonamides due to increased methotrexate toxicity. Monitor renal function, liver enzymes, and blood counts regularly. Contraindicated in pregnancy, breastfeeding, and active infections.
Agrylin (anagrelide) is a phosphodiesterase III inhibitor used to reduce platelet counts in essential thrombocythemia. Monitor platelet count weekly during titration; target <600,000/µL. Avoid in patients with severe hepatic impairment (Child-Pugh C). Use with caution in cardiac disease due to risk of QT prolongation and arrhythmias. Anagrelide may increase bleeding risk, especially when combined with anticoagulants or NSAIDs. Discontinue 4-5 days before elective surgery.
Take exactly as prescribed; do not change dose without consulting your doctor.,Avoid alcohol completely while on this medication.,Report any signs of infection (fever, sore throat), unusual bleeding, or mouth ulcers immediately.,Use effective contraception during treatment and for at least 3 months after stopping.,Do not take any over-the-counter medications, especially NSAIDs (ibuprofen, naproxen), without permission.,Drink plenty of fluids to prevent kidney damage.,Attend all scheduled blood tests and appointments.,Capsules should be swallowed whole; do not crush or chew.
Take exactly as prescribed; do not skip doses or double up.,Report any signs of bleeding (easy bruising, nosebleeds, black/tarry stools) or palpitations immediately.,Avoid NSAIDs like ibuprofen and aspirin unless directed by your doctor.,Do not consume grapefruit or grapefruit juice while taking this medication.,Inform all healthcare providers (including dentists) that you are on anagrelide.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MEXATE-AQ vs AGRYLIN, answered by our medical review team.
MEXATE-AQ is a Antineoplastic Agent that works by Methotrexate is a folate analog that inhibits dihydrofolate reductase (DHFR), blocking the conversion of dihydrofolate to tetrahydrofolate, which is required for the synthesis of purines and pyrimidines. This leads to inhibition of DNA, RNA, and protein synthesis, particularly in rapidly dividing cells. It also has immunosuppressive effects via inhibition of T cell activation and reduction of inflammatory cytokines.. AGRYLIN is a Antineoplastic Agent that works by Agrylin (anagrelide) inhibits cyclic nucleotide phosphodiesterase III (PDE3) and reduces platelet production by interfering with megakaryocyte maturation and proliferation, likely via inhibition of cyclic AMP phosphodiesterase and modulation of intracellular calcium levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MEXATE-AQ and AGRYLIN depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MEXATE-AQ is: Methotrexate: 7.5-25 mg orally once weekly for rheumatoid arthritis; 30-40 mg/m2 IV weekly for mycosis fungoides; 50-75 mg/m2 IV over 4-6 hours weekly for osteosarcoma; 15-20 mg/m2 IM weekly for psoriasis.. The standard adult dose of AGRYLIN is: Adults: 0.5 mg orally once or twice daily, increased by 0.5 mg every 2 weeks to maintain platelet count <600,000/µL. Maximum dose: 10 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MEXATE-AQ and AGRYLIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MEXATE-AQ is classified as Category C. FDA Pregnancy Category X. First trimester: High risk of miscarriage, CNS defects, craniofacial anomalies. Second trimester: IUGR, skeletal abnormalities. Third trimester: Neonatal . AGRYLIN is classified as Category C. Pregnancy Category C. Anagrelide is not recommended in pregnancy. Animal studies have shown embryotoxicity and teratogenicity (e.g., increased fetal resorptions, skeletal anomalies. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.